JP2025509510A5 - - Google Patents
Info
- Publication number
- JP2025509510A5 JP2025509510A5 JP2024554636A JP2024554636A JP2025509510A5 JP 2025509510 A5 JP2025509510 A5 JP 2025509510A5 JP 2024554636 A JP2024554636 A JP 2024554636A JP 2024554636 A JP2024554636 A JP 2024554636A JP 2025509510 A5 JP2025509510 A5 JP 2025509510A5
- Authority
- JP
- Japan
- Prior art keywords
- fdc
- breast cancer
- pharmaceutical product
- dose
- trastuzumab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263269326P | 2022-03-14 | 2022-03-14 | |
| US63/269,326 | 2022-03-14 | ||
| PCT/US2023/064143 WO2023178019A1 (en) | 2022-03-14 | 2023-03-10 | Combination therapies for breast cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025509510A JP2025509510A (ja) | 2025-04-11 |
| JP2025509510A5 true JP2025509510A5 (https=) | 2026-03-10 |
Family
ID=85937455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024554636A Pending JP2025509510A (ja) | 2022-03-14 | 2023-03-10 | 乳がんのための併用療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250177364A1 (https=) |
| EP (1) | EP4493180A1 (https=) |
| JP (1) | JP2025509510A (https=) |
| KR (1) | KR20240163084A (https=) |
| CN (1) | CN118843461A (https=) |
| AU (1) | AU2023234511A1 (https=) |
| CA (1) | CA3254271A1 (https=) |
| IL (1) | IL315153A (https=) |
| MX (1) | MX2024011183A (https=) |
| TW (1) | TW202400230A (https=) |
| WO (1) | WO2023178019A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| IL301603A (en) | 2011-10-14 | 2023-05-01 | Genentech Inc | Pertuzumab, trastuzumab, docetaxel and carboplatin for use in the preoperative treatment of a patient |
| MX368259B (es) | 2013-04-16 | 2019-09-25 | Genentech Inc | Variantes de pertuzumab y su evaluacion. |
| PT3589661T (pt) | 2017-03-02 | 2024-01-29 | Genentech Inc | Tratamento com adjuvante de cancro da mama positivo para her2 |
| JP2023532122A (ja) | 2020-06-29 | 2023-07-26 | ジェネンテック， インコーポレイテッド | ペルツズマブにトラスツズマブを加えた固定用量配合剤 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000042133A1 (en) | 1999-01-15 | 2000-07-20 | Infineum International Ltd | Improved fuel compositions |
| TW202508629A (zh) | 2017-01-17 | 2025-03-01 | 美商建南德克公司 | 皮下her2抗體調配物 |
| CN115551513B (zh) * | 2020-05-12 | 2025-05-02 | 基因泰克公司 | 使用包含gdc-9545和cdk4/6抑制剂的组合疗法治疗乳腺癌 |
| JP2023532122A (ja) | 2020-06-29 | 2023-07-26 | ジェネンテック， インコーポレイテッド | ペルツズマブにトラスツズマブを加えた固定用量配合剤 |
| JP2023533813A (ja) | 2020-07-14 | 2023-08-04 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 一定用量配合剤のアッセイ |
-
2023
- 2023-03-10 KR KR1020247031992A patent/KR20240163084A/ko active Pending
- 2023-03-10 WO PCT/US2023/064143 patent/WO2023178019A1/en not_active Ceased
- 2023-03-10 IL IL315153A patent/IL315153A/en unknown
- 2023-03-10 CN CN202380026682.0A patent/CN118843461A/zh active Pending
- 2023-03-10 MX MX2024011183A patent/MX2024011183A/es unknown
- 2023-03-10 TW TW112109034A patent/TW202400230A/zh unknown
- 2023-03-10 CA CA3254271A patent/CA3254271A1/en active Pending
- 2023-03-10 EP EP23715700.3A patent/EP4493180A1/en active Pending
- 2023-03-10 AU AU2023234511A patent/AU2023234511A1/en active Pending
- 2023-03-10 JP JP2024554636A patent/JP2025509510A/ja active Pending
- 2023-03-10 US US18/844,654 patent/US20250177364A1/en active Pending